TipRanks
Advertisement
Advertisement
Mesoblast revenue surges on RYONCIL launch as late‑stage pipeline advances
PremiumCompany AnnouncementsMesoblast revenue surges on RYONCIL launch as late‑stage pipeline advances
2M ago
Mesoblast Flags Risks Around 2026 Outlook and Stem Cell Strategy
Premium
Company Announcements
Mesoblast Flags Risks Around 2026 Outlook and Stem Cell Strategy
2M ago
Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer
Premium
Company Announcements
Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer
2M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
2M ago
Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial
Premium
The Fly
Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial
2M ago
Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial
Premium
Company Announcements
Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial
2M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
3M ago
Mesoblast Cancels Over 1.2 Million Lapsed Options
Premium
Company Announcements
Mesoblast Cancels Over 1.2 Million Lapsed Options
3M ago
Mesoblast Expands Ordinary Share Base Through Conversion of Unquoted Securities
Premium
Company Announcements
Mesoblast Expands Ordinary Share Base Through Conversion of Unquoted Securities
3M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―